Participating in clinical trials
Having been diagnosed with melanoma you may be offered participation in a clinical trial or research study.
Why Should I Join a Trial?
People choose to participate in trials for different reasons. There are benefits and risks involved in joining any trial.
The benefits are:
You have an active role in your own healthcare
You can access new research treatments
You may experience a treatment benefit
You will possibly help others including your own children and grandchildren by contributing to medical research
You will experience personalised care and attention
You will increase your knowledge about melanoma and its treatment
The risks are:
The experimental treatment may not be effective for you
You may experience side effects of the experimental treatment
The trial may require more of your time and attention including more trips to the study site, more treatments and more investigations
Please remember that clinical trial participation is voluntary. You may withdraw from a trial at any time without affecting your ongoing care.
Choosing to participate in a clinical trial is an important decision. Informed consent is the process of gathering and understanding the information about a trial in order to make an informed decision on whether or not you want to be a part of the trial.
You will always receive written information, the “Information for Participants” and the Consent Form for the specific trial you are being asked to consider, and you will be given ample opportunity to discuss that trial with your doctor and trial staff. The “Information for Participants” document includes details about the trial such as the aim, procedures involved, duration, alternative treatment options, risks, benefits, costs and key contact details.
When you feel that you are fully informed, you can decide whether to participate or not. If you choose to participate you will be required to sign the Consent Form. A signed copy of this form will be given to you for your records. Informed consent is also a continuing process throughout the trial providing participants with any new information that may affect their continuation in